Featured Research

from universities, journals, and other organizations

Human and canine lymphomas share molecular similarities, first large-scale comparison shows

Date:
June 25, 2013
Source:
University of North Carolina School of Medicine
Summary:
Humans and their pet dogs are close, so close that they both develop a type of cancer called diffuse large B-cell lymphoma. In humans it’s the most common lymphoma subtype while in dogs, it’s one of the most common cancers in veterinary oncology.

Humans and their pet dogs are close, so close that they both develop a type of cancer called diffuse large B-cell lymphoma. In humans it's the most common lymphoma subtype while in dogs, it's one of the most common cancers in veterinary oncology.

A team of scientists from the University of North Carolina School of Medicine, North Carolina State University's College of Veterinary Medicine and Duke University have conducted one of the first studies to directly compare canine and human B-cell lymphoma by examining molecular similarities and differences between the two species.

The study was published June 19, 2013 online in the journal Cancer Research.

Kristy Richards, MD, PhD, corresponding author, said, "Comparing the molecular similarities of lymphomas across species has allowed us to see what parts of lymphoma development and growth are evolutionarily conserved. This teaches us more about what components of human lymphoma biology are most fundamental and critical. The canine lymphoma work is now informing research on human lymphomas." Dr. Richards is an assistant professor of medicine and a member of UNC Lineberger Comprehensive Cancer Center.

"Pet dogs get cancer the same way humans do: at similar rates, and for unknown reasons. Like humans, dogs' tumors are spontaneously occurring, rather than genetically created as they are in mice, so canine tumors may more accurately mimic the situation in human cancer patients. Dogs are good models to study, because it will also be possible to study shared risk factors, in the environment, for example, that might predispose both humans and dogs to get lymphoma. Our knowledge helps dogs and humans with lymphoma.

"Veterinarians treating dogs for lymphoma can offer clinical trials to their owners. Clinical trials in dogs are similar to those done in humans, with safety protections in place to minimize harm.

"What we have learned in our study could facilitate faster, more efficient new drug development, allowing new therapies to get to cancer patients faster and with a higher likelihood of success."

Molecular analyses of canine and human tumors were completed at NCSU and at UNC Lineberger. The team used gene expression profiling and found that canine B-cell lymphoma expression profiles were similar in many ways to human B-cell lymphoma, thus paving the way for future studies, including therapeutic clinical trials in dogs and humans.

Senior study author is Dr. Steven Suter, associate professor of medical oncology at the NCSU College of Veterinary Medicine. Other authors from NCSU are Alison Motsinger-Reif, Hsiao-wei Chin, Dahlia Nielsen, Rachael Thomas, Chris Smith, Matthew Breen, and Luke Borst. Sandeep Dave from Duke University was an author and other authors from UNC are Yuri Fedoriw, Cheng Fan, George Small and Charles Perou.

The work was supported by a developmental grant from the University Cancer Research Fund.


Story Source:

The above story is based on materials provided by University of North Carolina School of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. K. L. Richards, A. A. Motsinger-Reif, H.-w. Chen, Y. Fedoriw, C. Fan, D. M. Nielsen, G. W. Small, R. Thomas, C. Smith, S. S. Dave, C. M. Perou, M. Breen, L. B. Borst, S. E. Suter. Gene profiling of canine B-cell lymphoma reveals germinal center and post-germinal center subtypes with different survival times, modeling human DLBCL. Cancer Research, 2013; DOI: 10.1158/0008-5472.CAN-12-3546

Cite This Page:

University of North Carolina School of Medicine. "Human and canine lymphomas share molecular similarities, first large-scale comparison shows." ScienceDaily. ScienceDaily, 25 June 2013. <www.sciencedaily.com/releases/2013/06/130625140935.htm>.
University of North Carolina School of Medicine. (2013, June 25). Human and canine lymphomas share molecular similarities, first large-scale comparison shows. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/06/130625140935.htm
University of North Carolina School of Medicine. "Human and canine lymphomas share molecular similarities, first large-scale comparison shows." ScienceDaily. www.sciencedaily.com/releases/2013/06/130625140935.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins